| Literature DB >> 12067102 |
Tae Han Yuk1, Joon Hyeog Kang, Sang Ryoung Lee, Sang Won Yuk, Kwang Gyu Lee, Beum Yong Song, Cheorl Ho Kim, Dong Wook Kim, Il Kim Dong, Tae Kyun Lee, Chang Hyun Lee.
Abstract
Anti-bone resorption properties of the Korean herbal formulation, Honghwain (HHI; Carthamus tinctorius L. seed) was biochemically investigated. On processing bone metabolism, PGE2 accelerated production of IL-1beta in fetal mouse osteoblast and stimulated physiological activation substance, IL-1beta. The novel class of Src tyrosine kinase inhibitors, Herbimycin A (HERB) and HHI reduced COX-2 mRNA levels as well as PGE2 production induced by IL-1beta, TNF-alpha and IL-6. HHI inhibited in vitro and in vivo bone resorption by inhibition of phosphorylation of peptide substrates. HHI dose-dependently reduced the hypercalcemia induced in mice by IL-1beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. These results indicate that the synergy between IL-beta, TNF-alpha, IL-6 on PGE2 production is due to an enhanced gene expression of COX-2 and that tyrosine kinase (s) are involved in the signal transduction of COX-2 in mouse calvarial osteoblasts. Thus, HHI as a possible Src family kinase inhibitor may be useful for the treatment of diseases associated with elevated bone loss.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12067102 DOI: 10.1142/S0192415X02000119
Source DB: PubMed Journal: Am J Chin Med ISSN: 0192-415X Impact factor: 4.667